Horizon Discovery

Horizon Discovery is a life sciences company specializing in gene editing and gene modulation technologies. Founded in 2007 by Dr. Chris Torrance and Professor Alberto Bardelli, the company originated in Cambridge, UK. They were later joined by Dr. Darrin M. Disley. The company's foundation was built on a gene-editing platform, rAAV, which enables the creation of custom-engineered cell lines with specific genomic modifications.

The company's business model focuses on providing products, services, and research programs to clients across the healthcare spectrum, from initial research to therapeutic applications. It offers a comprehensive portfolio of tools and services based on technologies like CRISPR, RNAi, and base editing. These offerings help scientists understand gene function and the genetic drivers of diseases, which is crucial for developing new drugs and therapies. Horizon serves a global client base that includes major pharmaceutical, biotechnology, and diagnostic companies, as well as academic research centers.

The product line includes over 23,000 items, such as isogenic cell lines, engineered haploid cells, molecular reference standards, and various reagents. These products function as "patients-in-a-test-tube," allowing researchers to model diseases and test the efficacy of potential drugs in a laboratory setting. Services include custom cell line engineering, drug screening, target identification, and bioproduction. In November 2020, PerkinElmer acquired Horizon Discovery for approximately $383 million. Following a corporate split at PerkinElmer, Horizon became part of the newly formed Revvity, Inc. in May 2023.

Keywords: gene editing, gene modulation, cell engineering, CRISPR, RNAi, translational genomics, molecular reference standards, cell lines, drug discovery, bioproduction, personalized medicine, genomic research, disease models, target identification, target validation, drug screening, biopharmaceutical development, base editing, cell therapy